Please read  FDA's risk-based  approach guidance and EMA's reflection paper on risk-based  approach to  quality management. Both are also posted within the BlackBoard  system  and can be found on FDA and EMA's website. Please answer the following   questions:
- How are  these documents similar? How different? Provide a brief summary of each that  allows for this comparison.
 
- After   reviewing these guidance documents do you believe taking a risk-based  approach  involves 'taking short-cuts'? Why or why not?
 
- Do you   believe it is possible to achieve a higher level of quality by taking  a  targeted approach to data review as opposed to implementing 100% review   strategy? Why or why not?
 
Please provide a two page paper addressing the  above-referenced questions